Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2018
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 21 Mar 2017 Status changed from recruiting to discontinued due to toxicity.
- 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.